Aurobindo Pharma Limited — Important, 26-05-2025: General Updates

Aurobindo Pharma’s subsidiary, Lyfius Pharma, faced a safety incident causing an estimated loss of Rs. 4 Cr. Production is on hold awaiting operational consent from the Andhra Pradesh Pollution Control Board. The company is pursuing an insurance claim to recover the loss, with operations set to resume after approval. No additional financial impact has been shared.